Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

23.29 -0.02 (-0.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.